BGI Genomics (BGI), founded in China in 1999, covered the entire field of genomic sequencing applications. During the COVID-19 pandemic in 2020, BGI’s strategic corporate social responsibility initiative, developing coronavirus nucleic acid test kits, created shared value for BGI and society; brought revenue growth to the company; and won BGI acclamation from the government, media, and public. However, as the market competition in the COVID-19 testing business intensified, Zhao Lijian, chief executive officer of BGI, had to consider the company’s next direction: Should BGI significantly increase investment in the COVID-19 testing business and shoulder greater social responsibility for fighting the pandemic? Or should it shift the focus back to its main business?

BGI Genomics (BGI), founded in China in 1999, covered the entire field of genomic sequencing applications. During the COVID-19 pandemic in 2020, BGI's strategic corporate social responsibility initiative, developing coronavirus nucleic acid test kits, created shared value for BGI and society; brought revenue growth to the company; and won BGI acclamation from the government, media, and public. However, as the market competition in the COVID-19 testing business intensified, Zhao Lijian, chief executive officer of BGI, had to consider the company's next direction: Should BGI significantly increase investment in the COVID-19 testing business and shoulder greater social responsibility for fighting the pandemic? Or should it shift the focus back to its main business?